Adaptive Biotechnologies (NASDAQ:ADPT) Lowered to “Hold” Rating by Wall Street Zen

Wall Street Zen downgraded shares of Adaptive Biotechnologies (NASDAQ:ADPT) from a buy rating to a hold rating in a research note issued to investors on Saturday morning.

Several other analysts have also recently issued reports on ADPT. Guggenheim increased their target price on shares of Adaptive Biotechnologies from $20.00 to $21.00 and gave the stock a “buy” rating in a research note on Monday, January 26th. TD Cowen reiterated a “buy” rating on shares of Adaptive Biotechnologies in a research report on Wednesday, January 7th. Morgan Stanley assumed coverage on Adaptive Biotechnologies in a research report on Monday, December 1st. They set an “equal weight” rating and a $21.00 target price for the company. JPMorgan Chase & Co. upped their target price on Adaptive Biotechnologies from $17.00 to $20.00 and gave the stock an “overweight” rating in a research note on Thursday, November 6th. Finally, Piper Sandler lifted their price target on Adaptive Biotechnologies from $15.00 to $20.00 and gave the company an “overweight” rating in a research report on Wednesday, October 15th. Eight analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $17.22.

Adaptive Biotechnologies Trading Up 0.7%

ADPT opened at $18.50 on Friday. Adaptive Biotechnologies has a 12 month low of $6.26 and a 12 month high of $20.76. The company has a market cap of $2.82 billion, a PE ratio of -34.26 and a beta of 2.18. The company has a 50 day moving average of $17.29 and a 200 day moving average of $15.00.

Adaptive Biotechnologies (NASDAQ:ADPT) last posted its earnings results on Wednesday, November 5th. The company reported ($0.15) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.16) by $0.01. Adaptive Biotechnologies had a negative return on equity of 58.40% and a negative net margin of 31.50%.The firm had revenue of $93.97 million for the quarter, compared to the consensus estimate of $58.76 million. During the same quarter in the prior year, the business posted ($0.22) earnings per share. The business’s quarterly revenue was up 102.4% on a year-over-year basis. Research analysts forecast that Adaptive Biotechnologies will post -0.92 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Adaptive Biotechnologies news, insider Harlan S. Robins sold 10,000 shares of the stock in a transaction that occurred on Tuesday, January 6th. The shares were sold at an average price of $16.44, for a total transaction of $164,400.00. Following the transaction, the insider directly owned 1,222,312 shares in the company, valued at $20,094,809.28. This trade represents a 0.81% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Robert Hershberg sold 22,968 shares of the business’s stock in a transaction that occurred on Wednesday, December 10th. The stock was sold at an average price of $16.00, for a total transaction of $367,488.00. Following the completion of the sale, the director owned 46,722 shares of the company’s stock, valued at approximately $747,552. The trade was a 32.96% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold a total of 1,442,530 shares of company stock worth $24,610,748 over the last ninety days. Corporate insiders own 6.40% of the company’s stock.

Institutional Inflows and Outflows

Several large investors have recently modified their holdings of ADPT. Sound Income Strategies LLC bought a new stake in Adaptive Biotechnologies in the third quarter valued at approximately $30,000. Assetmark Inc. increased its stake in shares of Adaptive Biotechnologies by 867.9% in the fourth quarter. Assetmark Inc. now owns 3,020 shares of the company’s stock worth $49,000 after buying an additional 2,708 shares during the period. Smartleaf Asset Management LLC raised its holdings in Adaptive Biotechnologies by 593.5% during the 3rd quarter. Smartleaf Asset Management LLC now owns 3,939 shares of the company’s stock valued at $59,000 after buying an additional 3,371 shares during the last quarter. Caxton Associates LLP purchased a new stake in Adaptive Biotechnologies during the 1st quarter valued at $93,000. Finally, Mirae Asset Global Investments Co. Ltd. boosted its position in Adaptive Biotechnologies by 26.0% during the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 7,419 shares of the company’s stock valued at $120,000 after buying an additional 1,532 shares during the period. Hedge funds and other institutional investors own 99.17% of the company’s stock.

About Adaptive Biotechnologies

Adaptive Biotechnologies is a clinical-stage biotechnology company that focuses on harnessing the adaptive immune system to transform the diagnosis and treatment of disease. Through proprietary immune receptor sequencing and analysis, the company decodes the genetic information of T-cell and B-cell receptors to identify signatures of immune response. Its core technology platform provides insights into immune-driven conditions, enabling more precise monitoring and targeted therapeutic development.

The company’s flagship product, immunoSEQ, offers high-throughput immune repertoire profiling for researchers and pharmaceutical partners.